This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

IRWIN D. STEIN, M.D.; O. ALAN ROSE, M.D.

AMA Arch Intern Med. 1954;93(6):899-905.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THE medical management of thrombophlebitis, reliance is placed almost completely on bed rest with elevation of the extremity, hot or cold applications, and anticoagulant therapy. Analgesics are frequently used to control pain and antibiotics to combat the chills and fever which sometimes dominate the clinical picture. The latter are of doubtful value, except in the rare case of purulent or septic phlebitis due to bacterial organisms.

These measures, when aided by the factor of time, will cause resolution of the thrombophlebitis in most instances in from one to four weeks.

There remains, however, a small but important group in whom, despite such therapy, the inflammation in the veins and adjacent tissues may remain active, resulting in considerable disability and economic loss. An agent capable of producing rapid and sustained improvement or subsidence of the phlebitis in these refractory cases would be valuable.

Phenylbutazone (Butazolidin) has been found to bring . . . [Full Text PDF of this Article]

Author Affiliations
MT. VERNON, N. Y.; NEW YORK

Footnotes
Lecturer in Medicine (Peripheral Vascular Disease), Columbia University (Dr. Stein), and Assistant Professor of Clinical Medicine, New York University College of Medicine (Dr. Rose).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?